Severe nephrotic syndrome and early end-stage diabetic kidney disease in ABCC8-MODY12: A case report
Sophie Schmidt(Sigmund Freud Privatuniversität Wien), Gere Sunder–Plassmann(University of Vienna), Ursula Barnas(University of Vienna), Thomas Scherer(Medical University of Vienna), Alice Schmidt, Renate Kain(Medical University of Vienna), Peter Wolf(Medical University of Vienna), Christof Aigner(Medical University of Vienna), Nicolas Kozakowski(Medical University of Vienna)
Cited by 3
Related Papers
The Banff 2019 Kidney Meeting Report (I): Updates on and clarification of criteria for T cell– and antibody-mediated rejection
|American Journal of Transplantation|2020|809
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial
|The Lancet|2019|609
A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study
|The Lancet|2023|508
Erythropoietin Treatment of Anemia Associated with Multiple Myeloma
|New England Journal of Medicine|1990|450
Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document
|Orphanet Journal of Rare Diseases|2015|345